Table 2.
Characteristics of Related AEs Pre and Post-intervention in a VMMC Program Lilongwe, Malawi (2012)
| First audit | Repeat audit | p-value | |
|---|---|---|---|
| n = 3,000 | n = 2,540 | ||
| Severity | |||
| Mild | 6 (0.2) | 67 (2.6) | <0.001 |
| Moderate | 21 8 (7.3) | 28 (1.1) | |
| Severe | 33 (1.1) | 20 (0.8) | |
| Reportable (Moderate & Severe) | 251 (8.4) | 48 (1.9) | <0.001 |
| Type of AE | |||
| Infection | 161 (5.4) | 46 (1.8) | <0.001 |
| Hematoma | 24 (0.8) | 0 (0.0) | |
| Swelling | 15 (0.5) | 0 (0.0) | |
| Bleeding | 10 (0.3) | 37 (1.5) | |
| Wound disruption | 2 (0.1) | 16 (0.6) | |
| Delayed wound healing | 12 (0.4) | 3 (0.1) | |
| Damage to penis | 3 (0.1) | 1 (0.04) | |
| Insufficient skin removal | 4 (0.1) | 3 (0.1) | |
| Pain | 0 (0.0) | 5 (0.2) | |
| Urethral fistula | 0 (0.0) | 1 (0.04) | |
| Poor appearance | 1 (0.03) | 0 (0.0) | |
| Nonspecific or Unable to assess | 23 (0.8) | 0 (0.0) | |
| First Audit n=257 (8.6 %) | Repeat Audit n=115 (4.5 %) | p-value | |
| Appropriately treated | 25 (9.7) | 108 (93.9) | <0.001 |
| Median (range) number of drugs/AE | 2 (0–5) | 1 (1–2) | <0.001 |